GKOS · GLAUKOS Corp
$182.51
+1.94 (+1.07%)
At close · Aug 27
Market Cap
$10.70B
Shares
58.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$507.44M
+32.3%
FY2025
Net Income
-$187.69M
-28.2%
FY2025
Gross Margin
55.72%
-19.8pp
FY2025
Operating Margin
-39.33%
-7.4pp
FY2025
Diluted EPS
-$3.28
-18.4%
FY2025
Operating Cash Flow
-$14.79M
+75.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $680M – $700M | $612.84M | $507.44M | $383.48MG | $314.71MG | $282.86MG | $294.01M | $224.96M | $236.98M | $181.28M | $159.25M | $114.4M | $71.7M | $45.59M | $20.95M | |
| — | $127.96M | $111.81M | $94.03M | $75.58M | $68.98M | $66.63M | $91.72M | $38.59M | $25.08M | $21.05M | $16.18M | $12.99M | $11.42M | $2.54M | |
| — | $372.02M | $282.76M | $289.45M | $239.14M | $213.88M | $227.38M | $133.24M | $198.4M | $156.2M | $138.2M | $98.22M | $58.71M | $34.17M | $18.41M | |
| — | — | 55.72% | 75.48% | 75.99% | 75.61% | 77.34% | 59.23% | 83.72% | 86.17% | 86.78% | 85.86% | 81.89% | 74.95% | 87.9% | |
| — | $177.17M | $150.61M | $136.43M | $138.77M | $123.27M | $101M | $85.39M | $68.31M | $49.68M | $38.91M | $29.22M | $25.05M | $19.21M | $15.51M | |
| — | $386.7M | $331.75M | $261.17M | $224.07M | $192.93M | $179.26M | $171.4M | $176.64M | $119.53M | $96.26M | $64.76M | $43.96M | $28.14M | $17.1M | |
| — | — | $27.13M | $24.7M | $24.91M | $24.91M | $24.91M | $24.91M | — | — | — | $3.7M | $3.5M | $3.5M | $500K | |
| — | — | $38.09M | $35.65M | $33.65M | $31.58M | $29.66M | $29.38M | $6.31M | $6.26M | $5.48M | $4.72M | $4.27M | $4.23M | $1.16M | |
| — | — | — | — | — | — | — | — | $4.12M | — | — | — | — | — | — | |
| — | $565.37M | $482.36M | $411.82M | $367.84M | $296.2M | $260.26M | $256.79M | $248.69M | $169.21M | $140.49M | $93.98M | $69.01M | $47.34M | $32.61M | |
| — | -$193.36M | -$199.6M | -$122.37M | -$128.7M | -$82.31M | -$32.87M | -$123.55M | -$50.29M | -$13M | -$2.28M | $4.24M | -$10.3M | -$13.17M | -$14.2M | |
| — | — | -39.33% | -31.91% | -40.89% | -29.1% | -11.18% | -54.92% | -21.22% | -7.17% | -1.43% | 3.71% | -14.36% | -28.89% | -67.78% | |
| — | — | -$161.51M | -$86.72M | -$95.05M | -$50.74M | -$3.21M | -$94.17M | -$43.99M | -$6.74M | $3.2M | $8.96M | -$6.03M | -$8.94M | -$13.04M | |
| — | $4.91M | $4.64M | $10.04M | $13.63M | $13.72M | $13.37M | $14.12M | $2.57M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $82K | $3000 | $13K | |
| — | $523K | $6.56M | -$23.24M | -$5.03M | -$16.12M | -$16.4M | -$8.76M | $256K | $634K | $2.28M | $324K | -$27.99M | -$868K | -$23K | |
| — | -$192.83M | -$193.04M | -$145.6M | -$133.73M | -$98.43M | -$49.27M | -$132.31M | -$50.04M | -$12.37M | $1000 | $4.57M | -$38.29M | -$14.04M | -$14.22M | |
| — | -$4.79M | -$5.35M | $771K | $934K | $766K | $326K | -$11.97M | -$65.46M | $583K | $93K | $43K | $33K | $18K | $6000 | |
| — | -$188.05M | -$187.69M | -$146.37M | -$134.66M | -$99.2M | -$49.59M | -$120.35M | $15.42M | -$12.95M | -$92K | $4.52M | -$37.24M | -$12.13M | -$12.64M | |
| — | — | -36.99% | -38.17% | -42.79% | -35.07% | -16.87% | -53.5% | 6.51% | -7.14% | -0.06% | 3.95% | -51.94% | -26.6% | -60.34% | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$1.08M | -$1.93M | -$1.59M | |
| — | -$188.54M | -$187M | -$144.92M | -$130.52M | -$102.19M | -$50.58M | -$120.67M | $16.02M | -$11.62M | -$1.33M | $5.12M | -$37.23M | -$12.08M | -$12.64M | |
| USD/shares | — | -$3.27 | -$3.28 | -$2.77 | -$2.78 | -$2.09 | -$1.07 | -$2.70 | $0.41 | -$0.37 | $0.00 | $0.14 | -$2.13 | -$5.29 | — |
| USD/shares | — | -$3.27 | -$3.28 | -$2.77 | -$2.78 | -$2.09 | -$1.07 | -$2.70 | $0.37 | -$0.37 | $0.00 | $0.12 | -$2.13 | -$5.29 | — |
| shares | — | — | 57.19M | 52.76M | 48.43M | 47.44M | 46.42M | 44.5M | 37.36M | 35.32M | 34.38M | 32.93M | 17.47M | 2.29M | 2.04M |
| shares | — | — | 57.19M | 52.76M | 48.43M | 47.44M | 46.42M | 44.5M | 41.15M | 35.32M | 34.38M | 36.46M | 17.47M | 2.29M | 2.04M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.24×
EV/EBIT
—
Peer median 23.68×
P/E (TTM)
—
Peer median 28.38×
Peer medians compare against the 33 similar-size Medical Devices companies (of 146 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Development and Commercialization of Ophthalmic Therapies | $507,442,000 | $383,481,000 | $314,711,000 | $282,862,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $375,042,000 | $270,094,000 | $219,396,000 | $203,238,000 | $223,791,000 | $173,086,000 | $192,456,000 | $151,677,000 |
| Non Us | $132,400,000 | $113,387,000 | $95,315,000 | $79,624,000 | $70,220,000 | $51,873,000 | $44,528,000 | $29,601,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Glaucoma | $421,070,000 | $303,276,000 | $237,039,000 | $214,238,000 | $231,977,000 | $179,363,000 | $230,967,000 | $181,278,000 |
| Corneal Health | $86,372,000 | $80,205,000 | $77,672,000 | $68,624,000 | $62,034,000 | $45,596,000 | $6,017,000 | — |
Key facts
CIK
1192448
CUSIP
377322102
13F (30d)
300 filings
300 filers
Visit website
Investor relations